Table 6.

Changes in the Outcome Variables of the Subjects According to GNB3 Polymorphism

		Bofutsushosan
	Genotypea	Pre	Post	P valueb
Body weight, kg	C/C	70.53±8.77	69.33±7.6	.12
	C/T	75.33±13.11	74.16±12.58	.0147*
	T/T	74.75±9.04	73.82±9.26	.0705
BMI, kg/m2	C/C	27.52±1.17	27.1±0.66	.1486
	C/T	29.59±3.16	29.14±2.99	.0155*
	T/T	28.12±2.38	27.79±2.43	.077
WC, cm	C/C	95.8±8.38	93.07±6.4	.0488*
	C/T	97.49±6.99	95.9±7.24	.0206*
	T/T	96.91±7.31	95.19±6.33	.0581
Body fat percent	C/C	36.22±6.36	35.75±6.68	.5142
	C/T	39.2±4.95	38.64±5.18	.1148
	T/T	37±3.74	36.02±4.06	.0433*
Body fat mass, kg	C/C	25.28±4.03	24.5±3.93	.251
	C/T	29.52±6.64	28.54±5.93	.015*
	T/T	27.7±5.04	26.63±5.09	.0325*
RMR, kcal/d	C/C	1318.33±351.53	1448.33±217.39	.4527
	C/T	1434.17±445.61	1382.5±354.71	.6238
	T/T	1450±340.69	1449.17±279.56	.9938
TG, mg/dL	C/C	129.33±56.22	171.33±92.78	.2938
	C/T	122±56.33	108.04±38.32	.2592
	T/T	105±42.93	85.92±33.11	.0462*
T-Chol, mg/dL	C/C	187.33±20.29	195.83±34.14	.6638
	C/T	214.04±46.27	197.46±39.34	.0003*
	T/T	204.5±39.73	193.33±25.8	.2085
HDL-Chol, mg/dL	C/C	48.33±10.21	50.17±7.25	.2257
	C/T	57.08±14.06	52.83±12.17	.023*
	T/T	61.92±19.13	59.67±14.93	.398
Fasting BST, mg/dL	C/C	101±6.99	99.5±10.63	.6539
	C/T	96.5±8.67	96.13±6.73	.7912
	T/T	99.08±8.66	101.08±16.36	.5351
SBP, mmHg	C/C	115±1 2.98	112.17±13.69	.6535
	C/T	120.33±11.92	119.79±13.08	.7927
	T/T	122.42±14.85	118.25±14.16	.295
DBP, mmHg	C/C	71.67±8.66	75±12.07	.4765
	C/T	75.75±10.18	76.79±8.52	.5608
	T/T	79.58±5.73	71.5±9	.007*†
PR, bpm	C/C	80.67±14.51	76±10.04	.3493
	C/T	76.21±8.71	73.83±9.11	.1687
	T/T	75.33±8.69	73.08±7.22	.275

^aDistribution (number of patients): C/C, 7; C/T, 28; T/T, 18; unidentified, 2.

^bPre- vs. post-treatment (by paired t test).

^*P<.05.

^†Significant difference (P<.05) among the allelic variants (by one-way ANOVA).